The technology will be advanced under the company’s AortaCell™ and CerebraCell™ initiatives, with exclusive distribution rights assigned to Lionheart Health, Inc..
A New Paradigm in Aneurysm Care
Aneurysms, including abdominal and thoracic aortic aneurysms, remain a leading cause of life-threatening vascular events. Current treatment options are limited, often relying on surgical intervention or pharmacologic management that lacks precision and long-term compliance.
Leonhardt Ventures’ new platform introduces a non-drug, programmable alternative by leveraging bioelectric signals to activate Nrf2—a master regulator of antioxidant and cytoprotective responses known to:
- Reduce oxidative stress
- Suppress chronic inflammation
- Stabilize vascular tissue
- Prevent extracellular matrix degradation
“Instead of treating symptoms late in disease progression, we are targeting the underlying biology early,” said a company spokesperson. “By activating Nrf2 directly at the vascular level, we aim to stop aneurysms from growing—and potentially prevent them altogether.”
Multi-Modal Bioelectric Delivery System
The platform consists of three integrated delivery approaches:
1. Wearable Bioelectric Systems (BodStim™-Derived Suit or Vest)
A non-invasive garment embedded with multi-electrode arrays delivers optimized electrical signals across the thoracic and abdominal aorta to promote systemic vascular protection.
2. Implantable Bioelectric Aortic Stent / Coil
A next-generation endovascular device combines structural support with embedded electrodes, enabling localized stimulation directly within the vessel wall.
3. Hybrid Closed-Loop System
A combined implant-and-wearable approach allows external devices to wirelessly power and modulate implanted stimulators, enabling long-term, adaptive therapy.
Synergistic Regenerative Biology Integration
The platform is designed to work in combination with regenerative biologics, including:
- Klotho protein activation for vascular anti-aging and elasticity
- SDF-1 signaling to recruit stem cells for repair
- PDGF pathways to support smooth muscle cell survival
- Optional integration with VEGF, eNOS, and anti-inflammatory cytokines
This multi-pathway approach addresses the core drivers of aneurysm progression, including oxidative stress, inflammation, and cellular degeneration.
Broad Clinical and Preventative Applications
Potential use cases include:
- Stabilization of small aneurysms (<5 cm)
- Post-stent aneurysm management
- High-risk patient populations (e.g., smokers, hypertensive patients)
- Preventative vascular longevity programs
Scientific Foundation
The invention builds on extensive scientific evidence demonstrating:
- Nrf2 activation reduces aneurysm formation and progression
- Nrf2 deficiency accelerates vascular degeneration
- Electrical stimulation can modulate gene expression and regenerative pathways
- Klotho and SDF-1 play critical roles in vascular repair and longevity
Toward a New Class of Electroceutical Therapies
This innovation represents a major step forward in the emerging field of electroceuticals—therapies that use electrical signals to modulate biological function.
“This is not just a device—it’s a platform,” the company noted. “We are creating a new category of vascular therapies that combine bioelectric signaling with regenerative biology to extend healthspan and prevent catastrophic events.”
About Leonhardt Ventures LLC
Leonhardt Ventures LLC is a leader in bioelectric regenerative medicine, developing innovative therapies that use electrical signaling to activate the body’s natural healing mechanisms across cardiovascular, neurological, and longevity applications.
About Lionheart Health, Inc.
Lionheart Health, Inc. is a bioelectric medicine company focused on healthspan optimization, regenerative therapies, and clinic-based and at-home treatment platforms, with multiple FDA-cleared devices and a growing portfolio of bioelectric-enhanced therapies.
Media Contact:
Email: CS@lionhearthealthstim.com